Recombinant Human Biotinylated Mesothelin (C-6His-Avi)

Cat.No.: CY05

Biotinylated Human Mesothelin (C-6His-Avi)
Description
Biotinylated Recombinant Human Mesothelin is produced by our Mammalian expression system and the target gene encoding Glu296-Ser598 is expressed with a 6His, Avi tag at the C-terminus.
Accession #:AAH09272.1
Known as:Megakaryocyte potentiating factor; mesothelin; Pre-pro-megakaryocyte-potentiating factor; soluble MPF mesothelin related protein;CAK1; MPF; MSLN; SMR; CAK1; CAK1 antigen
Formulation
Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin:Less than 0.1 ng/?g (1 IEU/?g) as determined by LAL test.
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
Mesothelin is a cell surface glycoprotein whose expression is limited to mesothelial cells of the serosa (pleura, pericardium, and peritoneum) and epithelial cells of the trachea, tonsils, fallopian tube, and kidneys. Mesothelin plays an important role in cell survival, proliferation, migration, invasion, tumor progression, and resistance to chemotherapy. The overexpression of mesothelin can activate NF-κB and signal transducer and activator of transcription 3 (Stat3), inhibit apoptotic signaling and TNF-α-induced apoptosis, and accelerate the G1–S transition. Mesothelin is also found overexpressed in various cancers, including malignant mesothelioma, pancreatic or ovarian carcinoma, sarcomas and in some gastrointestinal or pulmonary carcinomas. As a result of its limited expression in normal tissues, mesothelin has been reported as an ideal tumor-associated marker for the development of targeted therapy.

Send Message